Data investigation
Judged Worse Than Not Losing Weight
Researchers gave 607 people identical descriptions of a stranger, varying only how they had lost weight. The version who used a GLP-1 was judged more harshly than the version who had not lost weight at all.
Researchers gave 607 people a short description of a stranger and asked what they thought of them. The descriptions were identical except for one detail: how the person had lost weight. The version who had used a GLP-1 was judged more harshly than the version who had dieted, and more harshly than the version who had not lost weight at all.[1]
What was done
The paper reports two randomized experiments. In each, participants read a brief history of a fictional person and then completed measures of weight-related stereotyping and willingness to associate with them. What varied between groups was only the weight history.
| The person was described as… | Result |
|---|---|
| Having lost weight using a GLP-1 | Rated most negatively |
| Having lost weight via diet and exercise | Rated better than the GLP-1 target (mean difference 0.52, 95% CI 0.27–0.76) |
| Not having lost weight | Also rated better than the GLP-1 target (0.26, 95% CI 0.02–0.51) |
People were less willing to associate with the person who lost weight on a GLP-1 than with the person who had not lost weight at all.
That last row is the finding. Weight stigma is well documented, and the expectation would be that losing weight reduces it. Here, losing it by this particular route left the person judged worse than if they had not lost it at all.
The second experiment locates it precisely
A second experiment with 706 participants added the situation people fear: regain. Targets were described as having regained weight after stopping a GLP-1, having regained after stopping a diet and exercise plan, never having lost weight, or having maintained a loss.
- After regain, the GLP-1 and diet-and-exercise targets were judged the same. The extra penalty for the drug disappeared.
- Both were judged worse than the person who maintained their loss (both P ≤ 0.001).
That is a sharper result than “people are judgmental about these drugs,” and it fits what patients report. Our interview-based coverage found stigma emerging as one of eight themes, varying by what the drug had been prescribed for (see eight things patients said). This is the experimental counterpart, and it puts a direction and a size on something people described from the inside.
What a vignette study can and cannot show
Stated attitudes and behavior can come apart, so do not read this as a measurement of what you will encounter.
The intervals matter too. Both gaps are in willingness to associate with the person. The gap against the diet-and-exercise target was 0.52 with an interval from 0.27 to 0.76, which is solid. The gap against the no weight loss target, which is the striking one, was 0.26 with an interval from 0.02 to 0.51. That barely excludes zero, on a scale that runs from 1 to 7. It is the most interesting finding here and the least firmly established.
Why it is worth knowing anyway
It names something people are told they are imagining. A patient who senses that disclosing this medication costs them something is not being oversensitive. There is experimental evidence that the disclosure changes how they are evaluated, in the direction they suspect.
It also bears on a practical decision that comes up constantly: whether to tell anyone. There are good clinical reasons to disclose. A medication missing from your record is invisible to interaction checking and to the team preparing a procedure, which we set out in what your doctor cannot see. Those reasons do not disappear because disclosure carries a social cost, and pretending the cost is not there helps nobody.
The authors’ own conclusion is that stigma follows people across the whole cycle of losing and regaining, and that stigma-reduction efforts belong in weight management. That is a reasonable thing to conclude from two experiments with fictional targets, stated at about the right strength.
Frequently Asked Questions
References
- 1.Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation International Journal of Obesity. 2026. PMID: 41933207.
Compare the sellers
Related research
The Mental Health Score That Did Not Move
In the head-to-head trial, physical quality-of-life scores improved clearly over 72 weeks. The Mental Component Summary did not significantly improve in either arm, a result the paper's own conclusion omits.
6 min read
Real, and Below the Threshold
Semaglutide improves patient-reported physical functioning by 1.71 points, with an interval excluding zero. The threshold at which a patient notices a change is 3.7 points. Both are true at once.
6 min read
A Quarter the Odds of Being Offered It
People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while having half again the odds of being put on insulin.
7 min read
Eight Things Patients Said
Trials measure weight and adverse events. They do not measure being judged for taking a drug. Researchers interviewed 30 people across 15 states and sorted what they said into eight themes.
6 min read
Antipsychotics and Metabolic Harm
The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.
7 min read
Does Ozempic or Mounjaro Cause Anxiety? What the Trials and Labels Show
In randomized trials, anxiety was no more common on semaglutide or tirzepatide than on placebo. Where cohort studies and adverse-event reports disagree, why low blood sugar and a faster pulse can feel like anxiety, and what is known about panic attacks.
12 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $179/mo
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →